 |
|
|
|
Ambler class |
Protein name |
PDB code |
Resolution (Å) |
Release date |
UniProt code |
PubMed ID |
DOI |
PDB |
Mutations |
Ligands |
Space group |
Unit cell parameters |
Z value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ||||||||
| B1 | VIM-7 | 2Y87 | 1.86 | 2011-06-15 | Q840P9 | 21645522 | 10.1016/J.JMB.2011.05.035 | pdb | MG UNX ZN | P 43 | 70.399 70.399 47.562 ♦ 90.00 90.00 90.00 | 4 | |
| B1 | VIM-7 | 2Y8A | 2.33 | 2011-06-15 | Q840P9 | 21645522 | 10.1016/J.JMB.2011.05.035 | pdb | MG UNX ZN | P 43 | 70.138 70.138 47.529 ♦ 90.00 90.00 90.00 | 4 | |
| B1 | VIM-7 | 2Y8B | 1.70 | 2011-06-15 | Q840P9 | 21645522 | 10.1016/J.JMB.2011.05.035 | pdb | OCS ZN | P 43 | 69.758 69.758 46.942 ♦ 90.00 90.00 90.00 | 4 | |
| B1 | VIM-7 | 4D1T | 1.25 | 2014-06-25 | Q840P9 | 24913158 | 10.1128/AAC.02735-13 | pdb | ZN | P 43 | 69.979 69.979 47.530 ♦ 90.00 90.00 90.00 | 4 | |
| B1 | VIM-7 | 4D1U | 1.80 | 2014-06-25 | Q840P9 | 24913158 | 10.1128/AAC.02735-13 | pdb | D120A | ZN | P 43 | 69.764 69.764 47.286 ♦ 90.00 90.00 90.00 | 4 |
| B1 | VIM-7 | 4D1V | 1.70 | 2014-06-25 | Q840P9 | 24913158 | 10.1128/AAC.02735-13 | pdb | F218Y | ZN | P 43 | 69.947 69.947 46.936 ♦ 90.00 90.00 90.00 | 4 |
| B1 | VIM-7 | 4D1W | 1.40 | 2014-06-25 | Q840P9 | 24913158 | 10.1128/AAC.02735-13 | pdb | H224Y | OCS ZN | P 43 | 70.225 70.225 47.027 ♦ 90.00 90.00 90.00 | 4 |
Statistics (number of structures): Overall (1663); class A (626); subclass B1 (403); subclass B2 (16); subclass B3 (104); class C (246); class D (268).
Last updated: November 20, 2024.
If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.
The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).
Contact: contact@bldb.eu